StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 7.3
Power Rank trend -> Falling
06/13/2025 16:00:00 EST
Neurocrine Biosciences Inc (NBIX)
Industry: Drug Manufacturers - Specialty & Generic
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, NBIX has been trading in a range between $125.73 and $119.12 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
NBIX is trading between resistance at $127.91 about 3% to the upside and support at $120.69 -3% to the downside. If it can break above the resistance, it could have some more upside to the next line of resistance at $153.29, about a 23% move. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Neurocrine Biosciences Inc $NBIX entered a Green zone 28 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $159.3952, a potential upside of 28.14% from the recent price of 124.39. The stock is trading 27% (potential upside) below its 52 week high of $157.98 and 47.68 % (potential downside) above its 52 week low of $84.23 - based on the recent price.
Company Summary
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia.
News
| Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer SAN DIEGO , June 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, an accomplished leader with 25 years of experience in information technology and artificial intelligence, will be responsible for driving the vision and long-term strategic direction of the company's technology initiatives. Source: PRNewsWire Mon, 09 Jun 2025 16:05:00 -0400 Sentiment: Neutral |
| CPRX or NBIX: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Neurocrine Biosciences (NBIX). But which of these two stocks is more attractive to value investors? Source: Zacks Investment Research Tue, 03 Jun 2025 12:40:16 -0400 Sentiment: Positive |
| Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 Tokyo, Japan and Cambridge, UK, 3 June 202 5 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine Biosciences (“Neurocrine”) has dosed the first patient in its Phase 3 registrational program of NBI-1117568 (NBI-'568) as a potential treatment for schizophrenia, resulting in a payment of US$15 million to Nxera (Clinical Trial ID: NCT06963034). The US$15 million payment will be fully recognized as revenue in the second quarter of 2025. Source: GlobeNewsWire Mon, 02 Jun 2025 19:30:00 -0400 Sentiment: Neutral |
| Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on tardive dyskinesia using multiple clinically validated scales Patients taking INGREZZA reported robust and clinically meaningful improvements in physical, social and emotional functioning Improvements were seen as early as Week 4 after initial treatment with the lowest INGREZZA dose and sustained through Week 24 Even patients with milder uncontrolled movement severity were negatively impacted by their tardive dyskinesia at baseline and demonstrated meaningful improvements in tardive dyskinesia impact with INGREZZA treatment SAN DIEGO , June 2, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 4 KINECT-PROTM open-label study demonstrating robust and sustained improvements in physical, social and emotional functioning in patients with tardive dyskinesia taking once-daily INGREZZA® (valbenazine) capsules. KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment, specifically INGREZZA, on tardive dyskinesia using multiple clinically validated scales, including the Tardive Dyskinesia Impact Scale. Source: PRNewsWire Mon, 02 Jun 2025 08:30:00 -0400 Sentiment: Neutral |
| Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 Tokyo, Japan and Cambridge, UK, 29 May 202 5 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Neurocrine Biosciences, Inc. announced that it had presented new positive data from the Phase 2 study of NBI-1117568 in adults with schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting in Scottsdale, Arizona. Source: GlobeNewsWire Wed, 28 May 2025 19:43:00 -0400 Sentiment: Neutral |
Technicals 52 Week Hi: 157.9799 52 Week Low: 84.23 Beta: 0.241 50 Day MA: 112.6306 200 Day MA: 121.4366 Earnings / Revenue Trends Qtr Earnings Growth YOY: -0.811 Qtr Revenue Growth YOY: 0.111 Forward PE: 24.1546 Trailing PE: 42.1661